Portfolio

Achillion Pharmaceuticals (NASD: ACHN), located in New Haven, Connecticut, is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital- based bacterial infections. Achillon completed its initial public offering in October 2006.

Avalon Pharmaceuticals (NASD: AVRX), located in Germantown, Maryland, is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. Avalon seeks to discover and develop novel therapeutics through the use of a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis, which it calls AvalonRx(R). This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response. Avalon completed its initial public offering in September 2005.

CardioFocus, based in Maynard, Massachusetts, is developing, manufacturing and marketing proprietary, disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias such as atrial fibrillation. The CardioFocus catheter promises rapid, effective and permanent isolation of the pulmonary veins while overcoming the difficulties inherent in the current RF ablation procedures. Guided via integrated endoscopic visualization, the catheter helps physicians to accomplish ablation by projecting a series of overlapping arcs of both visible and infrared laser light upon the atrial wall surrounding each vein. Complete isolation is generally obtained with several 60-second energy deliveries – promising a great advantage in speed and precision in comparison to the large number of ablations required in current RF ablation procedures.

Corixa Corporation, based in Seattle, WA, is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa was acquired by GlaxoSmithKline plc in July 2005 for $300 million. See the press release for details.

ISTA Pharmaceuticals (NASD: ISTA), based in Irvine, CA, is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products. ISTA's products and product candidates seek to address serious diseases and conditions of the eye such as dry eye, vitreous hemorrhage, diabetic retinopathy, hyphema, glaucoma, ocular pain and inflammation. Building on this pipeline, ISTA's goal is to continue its growth as a specialty pharmaceutical company by acquiring complementary products, either already marketed or in late-stage development.

Lumenos, based in Alexandria, VA, is one of the country’s leading providers of consumer-driven health care, an approach that’s sweeping away old ideas about how health care works. The Company’s goal is to improve consumers’ health outcomes, and by doing so, to achieve long- term cost efficiency for employers. Lumenos was acquired by Wellpoint, Inc. in June 2005 for $185 million. See the press release for details.

Magellan, based in Chelmsford, MA, serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for hospital-based labs and near-patient testing. Scientists use our discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness -- from disease pathology to biomarker identification. We design all of our systems, sensors, and consumables to deliver better, more-reliable results. And better results help drive improved health outcomes: earlier, more-accurate diagnoses; breakthroughs that can lead to novel treatments, new cures -- innovations to enhance life. A privately held company, Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TekCel.

Neuronetics, based in Malvern, PA, is an emerging medical device company focused on successfully developing and commercializing innovative, non-invasive therapies to treat psychiatric and neurological disorders using a technology called transcranial magnetic stimulation (TMS). TMS involves the use of very short pulses of magnetic energy to stimulate nerve cells in the brain. Neuronetics’ advanced TMS technology has completed investigation for the treatment of major depression in a series of integrated clinical trials. These trials evaluated its safety and ability to improve mood in major depression patients. Information from these trials will be submitted to the US Food and Drug Administration (FDA) to support clearance, which would ultimately allow US physicians to use Neuronetics’ technology to treat patients with symptoms of depression.

PneumRx, based in Mountain View, CA, develops minimally invasive medical devices for interventional pulmonary and thoracic surgery. The company is initially focused on devices and related technologies for chronic obstructive pulmonary disease and lung cancer. PneumRx received 510(k) notification from the FDA in November 2005 for its family of biopsy needles and kits.

Prolong Pharmaceuticals, based in Monmouth Junction, NJ, is a biopharmaceutical company whose core technology is an FDA approved delivery system for protein-based biopharmaceuticals, known as PEGylation. This process involves the chemical attachment of polyethylene glycol ("PEG") to a therapeutic protein. The result is a product that has significantly improved therapeutic properties, affords better patient compliance and reduced side effects. Prolong will develop long- acting biopharmaceuticals through its own research and by collaboration. These products may be sold by the company or licensed to third parties in other geographic areas.

Remon Medical Technologies, headquartered in Waltham, MA with operations in Caesarea, Israel, develops and commercializes smart, miniature implants that enable physicians to assess and treat a variety of medical conditions in a non-invasive manner. The Company's enabling technology utilizes wireless communications to exchange energy and data with miniature devices placed deep inside the body, in order to either monitor a variety of physiological parameters or to stimulate tissues and organs or to activate other devices, creating therapeutic responses. Remon's unique platform has broad applications for patient management, post-operative monitoring, nerve and tissue stimulation, and local drug delivery/release. Remon was acquired by Boston Scientific in August 2007. Please see the press release for details.

Scandius BioMedical, based in Littleton, MA, is a privately held medical device company that designs, manufactures and markets products for the orthopedic sports medicine market. The company was founded in 2000 and is focused on accelerating innovative solutions for minimally invasive orthopedic sports medicine procedures. Scandius has launched two revolutionary technologies addressing arthroscopic reconstruction of the torn anterior cruciate ligament, the StratisTM ST ACL Reconstruction System and the TriTisTM Tibial Fixation System. Scandius maintains a strong R&D pipeline focused on procedure specific products that treat a variety of sports-related injuries, with future developments addressing the areas of arthroscopic shoulder surgery, articular cartilage, and meniscal repair. Scandius was acquired by Covidien in November 2007. See the news article for details.

Scynexis is a chemistry-focused drug discovery and development company with its headquarters located in Research Triangle Park, North Carolina. SCYNEXIS offers a full spectrum of discovery and development transactions from fee-for-service projects to risk-sharing collaborations that could result in SCYNEXIS milestones, royalties and product rights. The company currently has product collaborations in the anti-fungal, anti- HIV, anti-HCV and animal health areas. SCYNEXIS fee-for-service capabilities range from concept to clinic, with services performed by teams integrating computational chemistry, medicinal chemistry, bioanalysis and process chemistry.